NASDAQ · Financial Statements

Repligen Corporation (RGEN) Revenue, Earnings & Financial Statements

$162.18 NASDAQ: RGEN Market Cap $10.37B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Repligen Corporation most recently reported annual revenue of $738.0M, net profit of $49.0M. Revenue grew at an average annual rate of 15.1% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Repligen Corporation: Revenue rose from $105.0M in 2016 to $738.0M in 2025, a change of +602.9% over 9 years; net profit was positive in 9 of 10 reported years; operating margin moved from 15.3% to 8.1%, a shift of -7.2 percentage points; the most recent year shows net profit of $49.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$105.0M$141.0M$194.0M$270.0M$366.0M$671.0M$802.0M$632.0M$634.0M$738.0M
Operating Expenses$89.0M$127.0M$168.0M$230.0M$285.0M$503.0M$577.0M$585.0M$670.0M$679.0M
Operating Profit$16.0M$14.0M$26.0M$40.0M$81.0M$167.0M$225.0M$48.0M−$35.0M$60.0M
Operating Margin15.3%9.9%13.4%14.8%22.2%24.9%28.0%7.5%-5.5%8.1%
Other Income−$4.0M−$7.0M−$5.0M−$14.0M−$22.0M−$14.0M−$6.0M$9.0M$8.0M$3.0M
Interest$4.0M$6.0M$7.0M$9.0M$12.0M$13.0M$3.0M$10.0M$23.0M$23.0M
Depreciation$5.0M$11.0M$16.0M$21.0M$27.0M$38.0M$57.0M$86.0M$87.0M$97.0M
Profit Before Tax$12.0M$7.0M$21.0M$26.0M$59.0M$154.0M$219.0M$57.0M−$27.0M$62.0M
Tax rate (%)0.1%-291.2%22.5%18.1%-1.2%16.4%15.1%37.2%5.6%21.6%
Net Profit$12.0M$28.0M$17.0M$21.0M$60.0M$128.0M$186.0M$36.0M−$26.0M$49.0M
EPS$0.34$0.72$0.37$0.44$1.11$2.24$3.24$0.63−$0.46$0.86

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$156.0M$153.0M$159.0M$155.0M$168.0M$169.0M$182.0M$189.0M$198.0M$194.0M$204.0M$209.0M
Operating Expenses$157.0M$149.0M$151.0M$163.0M$204.0M$163.0M$168.0M$172.0M$179.0M$176.0M$192.0M$239.0M
Operating Profit−$1.0M$4.0M$7.0M−$8.0M−$37.0M$7.0M$14.0M$17.0M$19.0M$18.0M$12.0M−$30.0M
Operating Margin-0.6%2.5%4.7%-5.1%-21.8%3.9%7.6%8.9%9.4%9.3%5.8%-14.1%
Interest$8.0M$6.0M$6.0M$6.0M$5.0M$6.0M$6.0M$27.0M$6.0M$6.0M$17.0M$6.0M
Profit Before Tax−$9.0M$4.0M$9.0M−$1.0M−$39.0M$8.0M$18.0M$17.0M$19.0M$2.0M$14.0M−$27.0M
Tax rate (%)-191.1%10.8%36.7%43.1%12.3%26.6%18.4%12.9%30.5%-370.3%64.6%-43.4%
Net Profit−$25.0M$3.0M$6.0M−$1.0M−$34.0M$6.0M$15.0M$15.0M$13.0M$8.0M$5.0M−$38.0M
EPS−$0.46$0.04$0.06$0.32−$0.60$0.10$0.26$0.26$0.23$0.15$0.09−$0.68

Over the 10 years reported for Repligen Corporation, borrowings increased from $95.0M in 2016 to $690.0M in 2025, cash stood at $566.0M in the latest year, shareholders' equity was $1.0M, current assets covered current liabilities 8.36 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$289.0M$120.0M$139.0M$1.4B$1.9B$2.4B$2.5B$2.8B$2.8B$3.0B
Current Assets$184.0M$243.0M$276.0M$642.0M$902.0M$932.0M$998.0M$1.1B$1.1B$1.1B
Cash$142.0M$174.0M$194.0M$528.0M$717.0M$604.0M$523.0M$751.0M$757.0M$566.0M
Inventory$25.0M$39.0M$42.0M$55.0M$95.0M$184.0M$238.0M$202.0M$143.0M$170.0M
Receivables$16.0M$28.0M$36.0M$44.0M$71.0M$117.0M$116.0M$124.0M$134.0M$159.0M
Fixed Assets$15.0M$22.0M$32.0M$74.0M$92.0M$227.0M$316.0M$323.0M$333.0M$306.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$100.0M$0$0$202.0M
Other Assets$60.0M$327.0M$327.0M$468.0M$618.0M$860.0M$856.0M$987.0M$1.0B$1.1B
Total Liabilities$120.0M$152.0M$159.0M$340.0M$374.0M$608.0M$621.0M$866.0M$857.0M$844.0M
Current Liabilities$21.0M$25.0M$130.0M$48.0M$319.0M$375.0M$404.0M$165.0M$127.0M$136.0M
Borrowings$95.0M$99.0M$103.0M$263.0M$275.0M$366.0M$423.0M$712.0M$686.0M$690.0M
Other Liabilities$25.0M$53.0M$56.0M$77.0M$98.0M$242.0M$198.0M$155.0M$171.0M$154.0M
Equity$0$0$0$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Reserves$169.0M$592.0M$616.0M$1.1B$1.5B$1.8B$1.9B$2.0B$2.0B$2.1B

For Repligen Corporation, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $94.0M; free cash flow was positive in 10 of 10 years; financing activities used $18.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$8.0M$17.0M$33.0M$67.0M$63.0M$119.0M$172.0M$114.0M$175.0M$117.0M
Investing Cash Flow−$54.0M−$104.0M−$31.0M−$228.0M−$228.0M−$288.0M−$367.0M−$162.0M−$119.0M−$322.0M
Financing Cash Flow$1.0M$1.0M$3.0M$1.0M$8.0M−$3.0M−$17.0M−$42.0M−$17.0M−$18.0M
Net Cash Flow$68.0M$52.0M$20.0M$344.0M$180.0M−$113.0M−$80.0M$228.0M$6.0M−$191.0M
Free Cash Flow$3.0M$12.0M$19.0M$44.0M$36.0M$52.0M$39.0M$75.0M$142.0M$94.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio7.11
Interest Coverage2.61
Return 1Y6.83%
Return 3Y8.09%
Return 5Y-41.34%

Repligen Corporation (RGEN) financials — frequently asked questions

What is Repligen Corporation's annual revenue?

Repligen Corporation (RGEN) reported annual revenue of $738.0M in its most recent fiscal year.

What is Repligen Corporation's net profit?

Repligen Corporation (RGEN) reported net profit of $49.0M in its most recent fiscal year.

Revenue and earnings of other Medical - Instruments & Supplies stocks

BDX revenue $19.5BMDLN stockWST revenue $3.1BSOLV revenue $8.3BBAX revenue $11.2BCOO revenue $4.1BAVTR revenue $6.6BATR revenue $3.8BBLCO revenue $5.1BTFX revenue $2.0BAll Medical - Instruments & Supplies stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
RGEN Overview RGEN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.